In addition, targeting DCLK1 with anti-DCLK1 monoclonal antibody (CBT-15) or siRNAs showed promising results in reducing tumor burden, cancer stemness, invasion, and metastasis [31,35,41,46,47,48,49,50,51,54,127,128,129,130,131,132,133,134]. This evidence concerns the gene DCLK1 and neoplasm.